EA200500776A1 - ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ - Google Patents

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ

Info

Publication number
EA200500776A1
EA200500776A1 EA200500776A EA200500776A EA200500776A1 EA 200500776 A1 EA200500776 A1 EA 200500776A1 EA 200500776 A EA200500776 A EA 200500776A EA 200500776 A EA200500776 A EA 200500776A EA 200500776 A1 EA200500776 A1 EA 200500776A1
Authority
EA
Eurasian Patent Office
Prior art keywords
function
serotoninin
norepinefrin
adrenoreceptora
disturbances
Prior art date
Application number
EA200500776A
Other languages
English (en)
Other versions
EA009781B1 (ru
Inventor
Людвиг Мельбургер
Мартин Михель
Марион Винрих
Урсула Эбингер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200500776A1 publication Critical patent/EA200500776A1/ru
Publication of EA009781B1 publication Critical patent/EA009781B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

В заявке описывается новая фармацевтическая композиция для лечения нарушений функции мочевого пузыря, содержащая ингибитор обратного захвата серотонина и/или норэпинефрина и агонист β-адренорецептора.Отчет о международном поиске был опубликован 2004.08.19.
EA200500776A 2002-11-27 2003-11-03 Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря EA009781B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PCT/EP2003/012225 WO2004047830A2 (de) 2002-11-27 2003-11-03 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen

Publications (2)

Publication Number Publication Date
EA200500776A1 true EA200500776A1 (ru) 2005-12-29
EA009781B1 EA009781B1 (ru) 2008-04-28

Family

ID=32241298

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500776A EA009781B1 (ru) 2002-11-27 2003-11-03 Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря

Country Status (22)

Country Link
US (2) US20090012161A9 (ru)
EP (4) EP1424079A1 (ru)
JP (2) JP2006509751A (ru)
KR (1) KR20050088295A (ru)
CN (1) CN1717230A (ru)
AT (1) ATE399005T1 (ru)
AU (2) AU2003285312A1 (ru)
BR (1) BR0316535A (ru)
CA (2) CA2507266A1 (ru)
CO (1) CO5580754A2 (ru)
DE (1) DE50310046D1 (ru)
EA (1) EA009781B1 (ru)
EC (1) ECSP055814A (ru)
ES (1) ES2309371T3 (ru)
HR (1) HRP20050467A2 (ru)
MX (1) MXPA05005483A (ru)
NO (1) NO20053088L (ru)
PL (1) PL376259A1 (ru)
RS (1) RS20050392A (ru)
UA (1) UA81931C2 (ru)
WO (2) WO2004047830A2 (ru)
ZA (1) ZA200503282B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
RU2006119331A (ru) * 2003-11-03 2007-12-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
CA2585037A1 (en) * 2004-10-26 2006-05-04 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
CA2599158C (en) * 2005-02-25 2011-01-25 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
EP1974725A4 (en) * 2006-01-10 2012-12-05 Kissei Pharmaceutical PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
CN101448493A (zh) * 2006-05-22 2009-06-03 特瓦制药工业有限公司 度洛西汀盐酸盐延迟释放配制剂
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
CA2704298C (en) * 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
JP5553767B2 (ja) * 2008-11-07 2014-07-16 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
KR20130135239A (ko) 2010-08-03 2013-12-10 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
TW201338772A (zh) * 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
BR112015005351A2 (pt) * 2012-09-18 2017-07-04 Taris Biomedical Llc sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR20180069865A (ko) 2015-10-15 2018-06-25 듀크 유니버시티 방광 기능장애를 치료할 수 있는 상태-의존적인 말초 신경제어
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
US20190307696A1 (en) 2016-04-25 2019-10-10 Synthon B.V. Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
AU715216B2 (en) * 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
AU715233B2 (en) * 1996-01-10 2000-01-20 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
RO117296B1 (ro) * 1996-03-11 2002-01-30 Lilly Co Eli Metoda pentru tratarea sau prevenirea cistitei interstitiale
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU731391B2 (en) * 1996-08-19 2001-03-29 Kissei Pharmaceutical Co. Ltd. Drug for the prevention or treatment of pollakiuria and urinary incontinence
TR199901063T2 (xx) * 1996-11-14 1999-08-23 Pfizer Inc. �kame edilmi� piridinler i�in i�lem.
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
ID23989A (id) * 1997-10-17 2000-06-14 Yamanouchi Pharma Co Ltd Turunan-turunan amida atau garam-garamnya
IL136612A (en) * 1997-12-18 2003-11-23 Kissei Pharmaceutical Phenylaminoalkyl-carboxylic acid derivatives and pharmaceutical compositions containing the same
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
WO1999051564A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
DE69919860T2 (de) * 1998-04-14 2005-08-25 Kissei Pharmaceutical Co., Ltd., Matsumoto 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
EA002720B1 (ru) * 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
ATE280167T1 (de) * 1999-07-23 2004-11-15 Pfizer Prod Inc Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
CZ304671B6 (cs) * 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
EP1286591B1 (en) * 2000-06-07 2010-10-06 Watson Pharmaceuticals, Inc. Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
US6696450B2 (en) * 2001-04-04 2004-02-24 Wyeth Serotonergic agents with long-acting in vivo effects
WO2003035600A1 (fr) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Procede de production de derive de benzocycloheptene
CA2464217A1 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Also Published As

Publication number Publication date
AU2003285312A1 (en) 2004-06-18
WO2004047838A2 (de) 2004-06-10
AU2003289854A1 (en) 2004-06-18
MXPA05005483A (es) 2005-08-16
JP2006509751A (ja) 2006-03-23
EP1640000A3 (de) 2007-01-17
BR0316535A (pt) 2005-10-04
CN1717230A (zh) 2006-01-04
CO5580754A2 (es) 2005-11-30
JP2006509752A (ja) 2006-03-23
EA009781B1 (ru) 2008-04-28
ECSP055814A (es) 2005-08-11
ZA200503282B (en) 2006-07-26
EP1572181B1 (de) 2008-06-25
US20050261369A1 (en) 2005-11-24
CA2507266A1 (en) 2004-06-10
ATE399005T1 (de) 2008-07-15
KR20050088295A (ko) 2005-09-05
WO2004047838A3 (de) 2004-10-28
EP1572181A2 (de) 2005-09-14
EP1567149A2 (de) 2005-08-31
HRP20050467A2 (en) 2006-06-30
US20090012161A9 (en) 2009-01-08
CA2507343A1 (en) 2005-07-14
PL376259A1 (en) 2005-12-27
RS20050392A (en) 2007-04-10
EP1640000A2 (de) 2006-03-29
ES2309371T3 (es) 2008-12-16
NO20053088L (no) 2005-06-23
EP1424079A1 (en) 2004-06-02
US20050261328A1 (en) 2005-11-24
UA81931C2 (ru) 2008-02-25
WO2004047830A2 (de) 2004-06-10
WO2004047830A3 (de) 2004-08-19
DE50310046D1 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
EA200500776A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ
MY134110A (en) Combinations of reboxetine and neuroleptic agents
BR0116206A (pt) Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
HK1079117A1 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
IL201038A0 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
EP1260221A3 (en) Combination treatment for depression and anxiety
EA200600531A1 (ru) Сочетание ингибитора обратного захвата серотонина и локсапина
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios
EA200600101A1 (ru) Лечение депрессии и других аффективных расстройств
SE9803156D0 (sv) A new composition
BRPI0413749A (pt) uso de amoxapina ou de um sal farmaceuticamente aceitável, composição farmacêutica, e, kit
EA200600183A1 (ru) Сочетание ингибитора обратного захвата серотонина и агомелатина
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина
ECSP034599A (es) Tratamiento de trastornos de ansiedad

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU